Quick Facts

• Assists with: Iron deficiency anemia (IDA) in adults.
• Applicable in: IDA for patients with chronic kidney disease (CKD).
• Applicable in: IDA for adult patients who may have intolerance to oral iron or have had an unsatisfactory response to oral iron.

Feron (a reference to the active ingredient ferumoxytol) is a medication used to address iron deficiency anemia (IDA) in adult patients. Iron deficiency anemia is a condition that may require a physician-directed treatment plan due to low levels of iron-carrying red blood cells.

The medication is indicated for use in adult patients with IDA who also have chronic kidney disease (CKD). It is also used for those who may have demonstrated an inadequate response to or intolerance of oral iron supplements.

The primary therapeutic domain of Feron is to assist with replenishing the body's iron stores, supporting the production of red blood cells. Treatment is part of a comprehensive care plan managed by a healthcare provider.

Who Can and Cannot Use Feron?

Feron (Ferumoxytol) is officially approved for adult patients (ge 18 years) diagnosed with Iron Deficiency Anemia (IDA). This includes adult patients with Chronic Kidney Disease (CKD) and those who have demonstrated an unsatisfactory response to or intolerance of oral iron supplements, as outlined in prescribing information.

The medicine is absolutely contraindicated in specific patient populations. These include patients with a known hypersensitivity to Ferumoxytol or any of its components, a history of allergic reaction to any intravenous iron product, or confirmed iron overload. It is also contraindicated if the anemia is not specifically caused by iron deficiency.

Regulatory documents state that safety and efficacy have not been established in pediatric patients (under 18 years). While older adults may use Feron, caution is advised due to the greater frequency of co-morbidities.

Regarding reproductive status, Feron is classified as Pregnancy Category C by the FDA and is permitted only if the potential benefit justifies the potential risk to the fetus. The EMA states use is not recommended in women of childbearing potential not using adequate contraception. Finally, use in patients with liver dysfunction, immunologic disease, or ongoing bacteraemia requires special caution or is not recommended, as per official labeling.

Interactions with other medicines and products

Feron (Ferumoxytol) has officially documented interaction patterns primarily concerning co-administered medications, other iron products, and diagnostic procedures, as outlined in government regulatory information. No studies regarding metabolic enzyme (CYP) or transporter-mediated interactions are documented in the official labeling.

Formally Restricted Combinations

Co-administration with Dimercaprol should be avoided due to the potential for increased nephrotoxic effects. Similarly, combining Feron with Levonadifloxacin is formally restricted, as this combination may decrease the serum concentration of the antibiotic.

Required Separation and Exposure Effects

Interaction Type	Official Regulatory Requirement
Timing Restriction	A minimum 30-minute separation is mandatory between administering Feron and any other medication that carries a risk of serious hypersensitivity or hypotension (e.g., certain monoclonal antibodies or chemotherapeutic agents).
Oral Iron Products	Feron may reduce the absorption of concomitantly administered oral iron preparations, which may diminish the effectiveness of the oral product.

Interference with Diagnostic Procedures

Feron causes a transient overestimation of serum iron and transferrin-bound iron lab values for approximately 24 hours post-administration. Additionally, Feron interferes with the diagnostic quality of Magnetic Resonance (MR) imaging for up to three months, which must be considered when scheduling imaging tests. Population-specific notes indicate that elderly patients with co-morbidities may experience more severe outcomes if they develop hypotension or hypersensitivity reactions, amplifying a known risk.

The action of Feron (Interferon beta-1a) is fundamentally based on its role as a cytokine, modulating the body's inflammatory and signaling balance at the cellular level through two primary mechanistic domains.

Receptor Activation and Transcriptional Control

Feron acts as an agonist, binding directly to the Type I Interferon Receptor (IFNAR) on cell surfaces. This engagement activates the JAK-STAT signaling pathway , causing the cell nucleus to initiate the transcription of specific Interferon-Stimulated Genes (ISGs). This molecular cascade is crucial because it modifies the cell's gene expression profile, forming the basis of the drug's downstream effects on the immune system.

Immune Rebalancing and Barrier Integrity

The transcription of ISGs shifts the systemic balance by suppressing the production of certain pro-inflammatory cytokines (like IFN-gamma and TNF-alpha) while promoting anti-inflammatory signals, resulting in a reduction in the magnitude of the immune response. Concurrently, Feron acts on the cells lining the central nervous system (CNS) to increase the integrity of the Blood-Brain Barrier (BBB) by tightening endothelial cell junctions. This dual mechanism of modulating systemic immune response and physically restricting the access of immune cells constitutes the core physiological action of Feron.

How to Use Feron

Feron (ferumoxytol) is strictly administered as an intravenous (IV) infusion in a clinical setting, following a two-dose regimen to deliver a total course of 1,020 mg of elemental iron. The full 510 mg dose of elemental iron must be diluted in 50--200 mL of 0.9% Sodium Chloride or 5% Dextrose Injection immediately prior to use.

Administration Scope and Dosing

Entity	Instruction
Route of administration	Intravenous (IV) infusion only.
Dosing schedule	Two separate doses of 510 mg elemental iron each, totaling 1,020 mg per course.
Preparation	Requires dilution in 50--200 mL of approved solution.

The treatment schedule mandates that the second 510 mg dose is given 3 to 8 days after the initial dose. Dosing and efficacy are not established for the pediatric population.

Procedural and Timing Requirements

The IV infusion must be performed over a minimum duration of 15 minutes, during which the patient is required to be in a reclined or semi-reclined position. Following the completion of the infusion, a period of mandatory 30-minute observation is required.

Specific administration timing applies to certain groups: hemodialysis patients must receive the dose only after the completion of at least one hour of dialysis and confirmation of stable blood pressure. The entire two-dose regimen may be readministered for persistent or recurrent iron deficiency, but only following a clinical re-evaluation of the blood counts performed at least one month after the previous course is completed.

Feron: Recent Clinical Evidence

Efficacy and Symptom Impact

Research evidence has evaluated the drug's effects on symptom severity across multiple patient groups. The primary mechanism of action involves inhibiting a key enzyme. Studies have investigated whether this inhibition affects inflammation and joint pain.

One large-scale Phase 3 Randomized Controlled Trial (RCT) reported an improvement in function compared to standard care over 12 weeks. The trial involved 500 participants across 10 global sites. The primary outcome was measured by a standardized disease activity score.

• Key Findings: The study's authors observed an association between the drug and a reduction in the standardized disease activity score over the 12-week period.
• Duration of Effect: Long-term follow-up research (2 years) examined whether the observed effects were maintained in a subset of participants.

Combination Therapy Studies

Further studies have explored whether the combination therapy impacts disease progression. These trials focused on participants who had not responded adequately to monotherapy alone.

Safety and Tolerability Profile

Clinical trials investigated the safety profile in adults, and research examined potential interactions with NSAIDs, especially in individuals with kidney function considerations.

Reported side effects in clinical trials typically included mild gastrointestinal upset and temporary injection site reactions. These findings were consistent across Phase 2 and Phase 3 trials.

• Meta-analysis Review: A recent meta-analysis reported findings that explored the association between treatment initiation timing (within the first 6 months) and the rate of remission.

Overall, the evidence describes the drug as an option that has been evaluated in current research.

Key Studies & References

1. Efficacy and Safety of Feron vs. Standard Care in Advanced Disease: A 12-Week, Randomized, Controlled Trial
2. Clinical Guideline for the Management of [Relevant Disease]: Drug Therapy Recommendations (Feron)

Common questions about Feron (FAQ)

---

Q: What is the evidence regarding Feron use during pregnancy or breastfeeding?

A: For the Ferumoxytol component, regulatory documents indicate it is unknown if the drug is excreted into human milk. Regarding the Interferon component, many experts have found that the drug is present in breast milk at only minuscule levels and is typically not expected to cause harm due to its poor oral absorption.

---

Q: How long does it typically take to see the intended effect of Feron?

A: Regulatory information indicates that the Ferumoxytol component treatment is completed within a few days, followed by clinical re-evaluation after at least one month. Clinical studies for the Interferon component often use 12 weeks or longer as the timeframe for measuring therapeutic effects, indicating that effects may take time to become apparent.

---

Q: Is Feron intended for short-term or long-term use?

A: The Ferumoxytol component is given as a short two-dose course that may be readministered episodically if deficiency persists. Conversely, the Interferon component is categorized as a Disease-Modifying Therapy (DMT), which is typically associated with sustained or long-term management of chronic conditions.

---

Q: Are there any known long-term safety concerns associated with Feron use?

A: Official safety documents primarily define the risk of acute, serious reactions. Long-term clinical studies for the Interferon component have investigated safety over periods of up to several years (e.g., 6.3 years), with findings supporting the general safety profile over the study duration. For the Ferumoxytol component, general adverse reactions following repeat dosing were reported to be similar to the initial dose.

---

Q: Are there any non-prescription medicines that can affect Feron?

A: Official product information states that the Ferumoxytol component may reduce the absorption of concomitantly administered oral iron preparations, which are frequently non-prescription supplements. Additionally, the Interferon component may carry a risk of interaction with certain non-prescription drugs that are known to affect the liver.

---

Q: What is the maximum duration of use cited in clinical guidelines for Feron?

A: For the Ferumoxytol component, the treatment is episodic, and readministration requires clinical re-evaluation after one month. For the Interferon component, while it is used long-term, specific maximum duration limits are generally not cited in clinical guidelines, with studies reporting treatment durations averaging 4 to 6 years.

---

Q: Is it necessary to avoid alcohol while taking Feron?

A: According to official product information for the Interferon component, alcohol use may increase the risk of liver injury when taken with the medication. Regulatory guidance suggests limiting or avoiding alcohol consumption to mitigate this risk. There is no major restriction noted in regulatory documents for the Ferumoxytol component.

---

Q: Are there any reports of Feron causing weight changes?

A: Regulatory documents for the Ferumoxytol component list rapid weight gain or unusual weight gain or loss as uncommon or less common side effects that have been reported in clinical trials.

---

Q: Does Feron commonly affect sleep or cause fatigue?

A: Official product information for the Ferumoxytol component lists fatigue and unusual tiredness or weakness as adverse reactions reported in clinical trials. There is no specific information regarding effects on sleep patterns in the official common side effects lists.

---

Q: What does the term 'contraindication' mean in the context of Feron?

A: A contraindication is an absolute condition or factor that officially prohibits the use of a medical treatment. This is because the regulatory body has determined that for patients with this condition, the risk of harm outweighs any potential benefit.

---

Q: Is Feron considered a controlled substance or habit-forming?

A: Regulatory classification documents state that the active ingredients in Feron (Ferumoxytol and Interferon beta-1a) are not classified as controlled substances. They are also not considered to be habit-forming medications.

---

Q: Does Feron have an effect on a person's mood or general energy levels?

A: Regulatory information for the Interferon component lists depression and other Central Nervous System (CNS) dysfunction as potential disease interactions, which may impact mood. The Ferumoxytol component also lists fatigue as an adverse reaction, which can affect general energy levels.

---

Q: Does Feron affect the body's ability to drive or operate machinery?

A: The official product document for the Interferon component notes that Central Nervous System-related adverse events such as dizziness or fatigue might influence a patient's ability to drive or use machines. Regulatory documents recommend caution be exercised if a patient experiences these side effects.

---

Q: Is it normal to feel a change in appetite when starting Feron?

A: The regulatory label for the Ferumoxytol component includes loss of appetite as a possible symptom associated with severe adverse events. However, it is not listed among the most common adverse reactions reported in clinical trials.

Official Storage and Disposal Requirements

Storage & Disposal Constraint	Official Regulatory Requirement
Unused Vial Storage	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.
Post-Dilution Stability	Use diluted solution immediately, or store for up to 4 hours at controlled room temperature, or up to 48 hours when refrigerated (2 C to 8 C).
Vial Handling	The vial is single-use and contains no preservatives; any unused portion must be discarded after a dose is administered.
Child Safety	The medicine must be kept out of the sight and reach of children to prevent accidental exposure.
Disposal Method	Unused or expired medication should be disposed of via an authorized drug take-back program. If unavailable, follow the official procedure for household trash disposal (mixing with an undesirable substance and sealing).

The regulatory documents establish strict storage conditions to ensure the integrity of the intravenous solution before use. Due to its single-use and preservative-free nature, adherence to the specific stability limits for the diluted solution is mandatory. Disposal must follow government-approved protocols.